TABLE 1.

Clinical and Utility Inputs

Major molecular response (12-month)
Imatinib alonea	0.37
Imatinib TDMb	0.65
Dasatinibc	0.52
Nilotiinibd	0.53
Switch ratese
Imatinib to dasatinib	0.50
Imatinib to nilotinib	0.50
Nilotinib to dasatinib	0.95
Nilotinib to imatinib	0.15
Dasatinib to nilontib	0.85
Dasatinib to imatinib	0.15
AP/BCe
Imatinib	0.07
Dasatinib	0.05
Nilotinib	0.04
Overall survivale
Imatinib	0.74
Dasatinib	0.75
Nilotinib	0.30
AP/BC	0.50
Utility
Baseline utility	0.75
Treatment response	0.90
AP/BC (first year)	0.60
AP/BC (after first year)	0.85
Treatment switch	0.58

^aRousselot P, Johnson-Ansah H, Huguet F, et al. Personalized daily doses of imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with chronic myeloid leukemia. Final results of the OPTIM TDM imatinib study in patients with CML. Blood. 2015;126(23):133.

^bKantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-70.

^cKantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123-9.

^dLarson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197-203.

^ePadula WV, Larson RA, Dusetzina SB, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108(7):djw003.

AP/BC = accelerated phase/blast crisis.